Does everolimus cause pneumonitis?

Does Everolimus Cause Pneumonitis?

Yes, everolimus definitively causes non-infectious pneumonitis—this is a well-established class effect of mTOR inhibitors that occurs in up to 19% of patients, with fatal outcomes reported. 1

Incidence and Severity

The FDA drug label explicitly warns that non-infectious pneumonitis is a class effect of rapamycin derivatives like everolimus 1. The incidence varies by indication:

• Overall incidence: up to 19% of patients across clinical trials 1
• Grade 3-4 pneumonitis: up to 4.2% combined 1
• Fatal cases have been documented 1

In specific populations, real-world data shows:

• 23% in neuroendocrine neoplasms (82% Grade 1-2,14% Grade 3,4% Grade 4) 2
• 52% in metastatic breast cancer (though only 31% symptomatic) 3
• 20% in neuroendocrine neoplasms in another cohort 4

The American College of Chest Physicians guidelines note that while pneumonia (infectious) occurred in 11.7% of lung transplant patients on everolimus, the toxicity profile includes increased serious infections, but the guideline does not specifically list non-infectious pneumonitis in its toxicity summary 5. However, this likely reflects the limited transplant-specific data rather than absence of risk.

Timing and Clinical Presentation

Pneumonitis typically occurs early in treatment:

• Median onset: 3.6 months (range 0.8-51 months) 2
• Over 80% of cases occur within the first 4 months of treatment 3
• Can occur even after dose reduction 1

Critical diagnostic consideration: Many patients are asymptomatic or minimally symptomatic despite radiographic findings. In one study, only 31% of patients with radiographically confirmed pneumonitis had symptoms 3. Another study found that imaging appears to overestimate the incidence of clinical pneumonitis 1.

When symptomatic, patients present with:

• Non-specific respiratory symptoms (cough, dyspnea)
• Fever
• Chest pain
• Exertional dyspnea 6, 7

Radiographic Patterns

CT findings typically show 8:

• Ground-glass opacities (most common)
• Organizing pneumonia pattern (bilateral, lower lobe predominant) 8, 6
• Reticular opacities
• Consolidation
• Bilateral and lower lung distribution is most characteristic 3

The Fleischner Society position paper specifically illustrates everolimus-induced pneumonitis with organizing pneumonia pattern 8.

Risk Factors

Elderly patients are at higher risk for developing pneumonitis 3. However, studies have not identified consistent predictors such as:

• Primary tumor site
• Concurrent lung disease
• Smoking history
• Prior therapies 2

Important caveat: Patients taking concurrent ACE inhibitors have increased risk of angioedema (6.8% vs 1.3%), which can present with respiratory symptoms 1.

Management Algorithm

For patients presenting with new respiratory symptoms on everolimus:

1. Consider pneumonitis in the differential immediately—do not assume infection 1

2. Obtain chest CT to assess for characteristic patterns 1

3. Rule out opportunistic infections, particularly Pneumocystis jiroveci pneumonia (PJP), as these patients are immunosuppressed 1

4. Grade the severity:

   • Grade 1 (asymptomatic, radiographic only): Continue everolimus without dose change, monitor closely 1
   • Grade 2 (symptomatic, not interfering with ADLs): Hold everolimus, consider corticosteroids 1
   • Grade 3 (interfering with ADLs, oxygen required): Hold everolimus, initiate corticosteroids, consider permanent discontinuation 1
   • Grade 4 (life-threatening): Permanently discontinue everolimus, aggressive corticosteroid therapy 1

5. If corticosteroids are initiated, provide PJP prophylaxis 1

6. Monitor for resolution: 54% of cases are reversible with dose reduction or discontinuation 9

Prognostic Implications

Paradoxically, everolimus-induced pneumonitis is associated with improved outcomes across multiple tumor types:

• Renal cell carcinoma: OS 24.7 vs 8.5 months (p<0.001), PFS 5.5 vs 3.2 months (p=0.002) 10
• Metastatic breast cancer: OS 42.8 vs 21.3 months (p=0.016), PFS 6.8 vs 4.1 months (p=0.024) 3
• Neuroendocrine neoplasms: OS 77 vs 52 months (p=0.093), with pneumonitis as independent predictor (HR 0.39, p=0.013) 2

This suggests pneumonitis may serve as a biomarker of everolimus efficacy 10, 3, though this should not change management of symptomatic or severe cases.

Key Clinical Pitfalls

1. Do not dismiss radiographic findings in asymptomatic patients—close monitoring is essential as progression can occur 1
2. Do not assume infection first—extensive infectious workup may delay appropriate management 6, 7, 11
3. Do not restart everolimus after Grade 3-4 pneumonitis—permanent discontinuation is recommended 1
4. Do not forget PJP prophylaxis when using corticosteroids in these already immunosuppressed patients 1
5. Baseline radiographic abnormalities do not exclude drug-induced pneumonitis—5 of 10 patients with Grade 3 pneumonitis had baseline radiological evidence before everolimus 9